tradingkey.logo
tradingkey.logo
Buscar

Neogenomics Inc

NEO
Añadir a la lista de seguimiento
14.970USD
+0.380+2.60%
Cierre 07/01, 16:00ETCotizaciones retrasadas 15 min
1.95BCap. mercado
PérdidaP/E TTM

Más Datos de Neogenomics Inc Compañía

NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.

Información de Neogenomics Inc

Símbolo de cotizaciónNEO
Nombre de la empresaNeogenomics Inc
Fecha de salida a bolsaDec 10, 2012
Director ejecutivoZook (Antony P)
Número de empleados2200
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 10
Dirección9490 Neogenomics Way
CiudadFORT MYERS
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal33912
Teléfono12397680600
Sitio Webhttps://neogenomics.com/
Símbolo de cotizaciónNEO
Fecha de salida a bolsaDec 10, 2012
Director ejecutivoZook (Antony P)

Ejecutivos de Neogenomics Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jeffrey Scott (Jeff) Sherman
Mr. Jeffrey Scott (Jeff) Sherman
Chief Financial Officer
Chief Financial Officer
220.01K
+0.96%
Mr. Warren Stone
Mr. Warren Stone
President, Chief Operating Officer
President, Chief Operating Officer
164.03K
+3.45%
Mr. Stephen Michael Kanovsky
Mr. Stephen Michael Kanovsky
Independent Director
Independent Director
75.42K
+30.60%
Dr. Neil Gunn
Dr. Neil Gunn
Independent Director
Independent Director
51.18K
+45.09%
Ms. Felicia Williams
Ms. Felicia Williams
Independent Director
Independent Director
30.24K
+76.32%
Ms. Marjorie C. Green
Ms. Marjorie C. Green
Independent Director
Independent Director
22.96K
--
Ms. Lynn A. Tetrault, J.D.
Ms. Lynn A. Tetrault, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Alison L. Hannah, M.D.
Dr. Alison L. Hannah, M.D.
Independent Director
Independent Director
--
--
Mr. Michael A. Kelly
Mr. Michael A. Kelly
Lead Independent Director
Lead Independent Director
--
--
Mr. David B. Perez
Mr. David B. Perez
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jeffrey Scott (Jeff) Sherman
Mr. Jeffrey Scott (Jeff) Sherman
Chief Financial Officer
Chief Financial Officer
220.01K
+0.96%
Mr. Warren Stone
Mr. Warren Stone
President, Chief Operating Officer
President, Chief Operating Officer
164.03K
+3.45%
Mr. Stephen Michael Kanovsky
Mr. Stephen Michael Kanovsky
Independent Director
Independent Director
75.42K
+30.60%
Dr. Neil Gunn
Dr. Neil Gunn
Independent Director
Independent Director
51.18K
+45.09%
Ms. Felicia Williams
Ms. Felicia Williams
Independent Director
Independent Director
30.24K
+76.32%
Ms. Marjorie C. Green
Ms. Marjorie C. Green
Independent Director
Independent Director
22.96K
--

Preguntas frecuentes

¿Quiénes son los cinco principales accionistas de Neogenomics Inc?

Los cinco principales accionistas de Neogenomics Inc son: Mr. Jeffrey Scott (Jeff) Sherman

¿Cuántas instituciones poseen acciones de Neogenomics Inc (NEO)?

A fecha de 2026Q1, 564 instituciones poseen acciones de Neogenomics Inc, con un valor de mercado combinado de aproximadamente 156.61M, lo que representa el 120.32% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 7515333.00.

¿Cuál es la mayor fuente de ganancias de Neogenomics Inc?

El 2026Q1, el segmento empresarial Clinical Services-Client direct billing generó la ganancia más alta para Neogenomics Inc, ascendiendo a 518.84M y representando el 71.34% de la ganancia total.